Merlin CP-GEP is the only molecular test recognized by NCCN as predictive and appropriate for use in select T1 and T2 patients to support shared decision-making regarding Sentinel Lymph Node Biopsy.
The MarketWatch News Department was not involved in the creation of this content. -- Sentinel lymph node (SLN) status alone is not sufficient as node negative patients still experience relapse and ...
Please provide your email address to receive an email when new articles are posted on . The Merlin test, a clinical-pathologic and gene expression profile, was able to successfully classify 37% of ...
New data analysis clarifies misleading benchmarks released by a competitor; separate SkylineDx analysis demonstrates Merlin CP-GEP Test provides stronger metastatic-risk stratification and superior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results